SCHEMBL7130913

SCHEMBL7130913

NC(=O)C(CCCNC(=O)OCc1ccccc1)C(=O)NCC(=O)C(O)CCc1ccccc1

nearest known ligand 0.47

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
HTT P42858 1/20 0.47
DPP8 Q6V1X1 2/20 0.46
DPP7 Q9UHL4 2/20 0.46
ANPEP P15144 1/20 0.44
LMNA P02545 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
SLC1A3 P43003 1/20 0.43
SLC1A1 P43005 1/20 0.43
TGM2 P21980 1/20 0.43
DPP4 P27487 1/20 0.43
DPP9 Q86TI2 1/20 0.43
KEAP1 Q14145 2/20 0.43
NFE2L2 Q16236 2/20 0.43
MMP2 P08253 1/20 0.43
MMP9 P14780 1/20 0.43
FOLH1 Q04609 2/20 0.42
MMP8 P22894 1/20 0.42
CTSL P07711 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7133716 0.94 SLC1A3 (0.47) HTTDPP8DPP7ANPEPLMNA
SCHEMBL25435146 0.81 HTT (0.62) HTTDPP8DPP7ANPEPLMNA
SCHEMBL7136804 0.80 HTT (0.51) HTTDPP8DPP7LMNASMN1; SMN2
SCHEMBL25413770 0.76 HTT (0.68) HTTDPP8DPP7ANPEPLMNA
SCHEMBL7130614 0.76 LMNA (0.45) HTTLMNASMN1; SMN2SLC1A3SLC1A1
SCHEMBL7137508 0.75 LMNA (0.44) HTTLMNASMN1; SMN2SLC1A3SLC1A1
SCHEMBL1586969 0.74 DPP8 (0.63) HTTDPP8DPP7ANPEPLMNA
SCHEMBL1586968 0.74 DPP8 (0.63) HTTDPP8DPP7ANPEPLMNA
SCHEMBL7134210 0.74 MMP3 (0.51) SMN1; SMN2FOLH1CTSL
SCHEMBL2139876 0.74 HTT (0.65) HTTDPP8DPP7ANPEPLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030092634-A1 Novel compounds and compositions as protease inhibitors AXYS PHARMACEUTICALS, INC. 2003-05-15 US disclosed
US-6506733-B1 Which process comprises hydrogenating a compound of Formula 9: presence of a catalytic amount of 20% palladium hydroxide on carbon. AXYS PHARMACEUTICALS, INC. 2003-01-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030092634-A1 Novel compounds and compositions as protease inhibitors SERPINB1, HPN, CTRL HTT 2706/4885DPP8 63/4885DPP7 69/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.